Shares in Noxopharm (ASX:NOX) jumped nearly 40% in morning trades on Wednesday according to Cboe live pricing as the company announced its experimental drug CRO-67 reduced human pancreatic tumour cells implanted into mice. The company reported significantly reduced pancreatic tumours as well as a reduction in barrier cells – literally, a barrier of cells that form around tumours and make delivering drugs difficult. Metastatic cancer spread significantly decreased, Noxopharm reported on Wednesday, and the drugs were handled well. Notably, tumour growth (as measured in the study) was reduced by …